ATE141051T1 - Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie - Google Patents

Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie

Info

Publication number: ATE141051T1
Authority: AT; Austria
Prior art keywords: melatonin; treatment; beneficient; production; bph
Prior art date: 1992-04-07

Application number

AT93302513T

Other languages

English (en)

Inventor

Nava Zisapel

Original Assignee

Neurim Pharma 1991

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-07

Filing date

1993-03-31

Publication date

1996-08-15

1993-03-31 Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991

1996-08-15 Application granted granted Critical

1996-08-15 Publication of ATE141051T1 publication Critical patent/ATE141051T1/de

Links

YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title abstract 4
229960003987 melatonin Drugs 0.000 title abstract 4
DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title abstract 4
238000004519 manufacturing process Methods 0.000 title abstract 2
206010020718 hyperplasia Diseases 0.000 title 1
229940126601 medicinal product Drugs 0.000 title 1
210000002307 prostate Anatomy 0.000 title 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 4
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
102000001419 Melatonin receptor Human genes 0.000 abstract 1
108050009605 Melatonin receptor Proteins 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
230000002280 anti-androgenic effect Effects 0.000 abstract 1
229940046836 anti-estrogen Drugs 0.000 abstract 1
230000001833 anti-estrogenic effect Effects 0.000 abstract 1
239000000051 antiandrogen Substances 0.000 abstract 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
239000000328 estrogen antagonist Substances 0.000 abstract 1
239000000122 growth hormone Substances 0.000 abstract 1
239000003966 growth inhibitor Substances 0.000 abstract 1
239000003607 modifier Substances 0.000 abstract 1
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 abstract 1
229960004535 oxazepam Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229960003604 testosterone Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT93302513T 1992-04-07 1993-03-31 Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie ATE141051T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US86468492A	1992-04-07	1992-04-07

Publications (1)

Publication Number	Publication Date
ATE141051T1 true ATE141051T1 (de)	1996-08-15

Family

ID=25343832

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93302513T ATE141051T1 (de)	1992-04-07	1993-03-31	Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie

Country Status (11)

Country	Link
US (2)	US5750557A (de)
EP (1)	EP0565296B1 (de)
JP (1)	JPH0640939A (de)
AT (1)	ATE141051T1 (de)
DE (1)	DE69303919T2 (de)
DK (1)	DK0565296T3 (de)
ES (1)	ES2090861T3 (de)
GR (1)	GR3021258T3 (de)
HK (1)	HK1006681A1 (de)
IL (1)	IL105240A (de)
SG (1)	SG41955A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUT75128A (en) *	1994-03-30	1997-04-28	Ciba Geigy Ag	Screening method using the rzr receptor family
EP0748627A3 (de) *	1995-06-14	1997-05-21	Lilly Co Eli	Melatoninagonisten zur Behandlung von gutartigen Hyperplasieformen der Prostata
ES2200334T3 (es) *	1997-04-07	2004-03-01	Wyeth	Estra-5(10),7-dieno con actividad estrogenica.
CN1414851A (zh) *	2000-01-05	2003-04-30	纽里姆药品(1991)有限公司	用于治疗对抗高血压药的抗药性和相关病症的方法和制剂
RU2221567C2 (ru) *	2000-08-25	2004-01-20	Санкт-Петербургская медицинская академия последипломного образования	Способ нормализации уровней клеточных факторов роста у мужчин с возрастным андрогенным дефицитом
IL144900A (en) *	2001-08-14	2013-12-31	Neurim Pharma 1991	Melatonin and medicaments comprising it for use in treating primary insomnia and in the manufacture of such medicaments
TWI271402B (en) *	2002-10-15	2007-01-21	Tanabe Seiyaku Co	Large conductance calcium-activated K channel opener
US9119846B2 (en)	2003-04-29	2015-09-01	Neurim Pharmaceuticals (1991) Ltd.	Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) *	2003-04-29	2013-12-31	Neurim Pharma 1991	Insomnia treatment
US7799817B2 (en) *	2004-02-20	2010-09-21	Lifescape Biosciences Inc	Compositions and methods for sleep regulation
AU2008228903B2 (en)	2007-03-19	2013-03-07	Vita Sciences, Llc	Transdermal patch and method for delivery of vitamin B12
US10849856B2 (en)	2016-10-31	2020-12-01	Neurim Pharmaceuticals Ltd.	Melatonin mini-tablets and method of manufacturing the same
PL3777842T3 (pl)	2016-10-31	2025-05-12	Neurim Pharmaceuticals Ltd.	Mini-tabletki melatoniny i sposób ich wytwarzania
CN114982720B (zh) *	2022-07-26	2024-02-13	贵州省人民医院	一种建立小鼠或大鼠雌雄激素失调型前列腺增生模型的方法
US12274680B2 (en)	2022-09-13	2025-04-15	II George William Creasy	Treatment of benign prostatic hypertrophy with capsinoids

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4600723A (en) *	1983-05-18	1986-07-15	Monash University	Method for minimizing disturbances in circadian rhythms of bodily performance and function
US4654361A (en) *	1986-01-27	1987-03-31	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Method of lowering intraocular pressure using melatonin
WO1988006009A1 (en) *	1987-02-13	1988-08-25	Maurizio Graziosi	System for making atoxic the shoe bottoms
US4855305A (en) *	1987-03-23	1989-08-08	Applied Medical Research	Compositions and methods of effecting contraception utilizing melatonin
GB8727099D0 (en) *	1987-11-19	1987-12-23	Cellena Cell Eng A G	Compositions containing melantonin/homologues
US4945103A (en) *	1989-01-17	1990-07-31	Michael Cohen	Method of treating pre-menstrual syndrome
IN171596B (de)	1989-06-27	1992-11-21	Cohen Michael
DE122007000073I1 (de)	1991-05-09	2008-01-31	Neurim Pharma 1991	Melatonin enthaltene Arzneimittel
US5196435A (en) *	1991-11-21	1993-03-23	Eli Lilly And Company	Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma

1993
- 1993-03-31 EP EP93302513A patent/EP0565296B1/de not_active Expired - Lifetime
- 1993-03-31 AT AT93302513T patent/ATE141051T1/de not_active IP Right Cessation
- 1993-03-31 IL IL10524093A patent/IL105240A/en not_active IP Right Cessation
- 1993-03-31 SG SG1995002001A patent/SG41955A1/en unknown
- 1993-03-31 ES ES93302513T patent/ES2090861T3/es not_active Expired - Lifetime
- 1993-03-31 DK DK93302513.2T patent/DK0565296T3/da active
- 1993-03-31 DE DE69303919T patent/DE69303919T2/de not_active Expired - Fee Related
- 1993-04-07 JP JP5080753A patent/JPH0640939A/ja active Pending
- 1993-08-24 US US08/111,014 patent/US5750557A/en not_active Expired - Fee Related
1996
- 1996-10-04 GR GR960402609T patent/GR3021258T3/el unknown
1997
- 1997-11-24 US US08/976,508 patent/US6048888A/en not_active Expired - Fee Related
1998
- 1998-06-23 HK HK98106095A patent/HK1006681A1/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0565296B1 (de)	1996-08-07
US5750557A (en)	1998-05-12
DE69303919D1 (de)	1996-09-12
DK0565296T3 (da)	1996-12-09
DE69303919T2 (de)	1997-01-30
HK1006681A1 (en)	1999-03-12
EP0565296A1 (de)	1993-10-13
IL105240A0 (en)	1993-07-08
ES2090861T3 (es)	1996-10-16
GR3021258T3 (en)	1997-01-31
JPH0640939A (ja)	1994-02-15
SG41955A1 (en)	1997-08-15
IL105240A (en)	1999-04-11
US6048888A (en)	2000-04-11

Similar Documents

Publication	Publication Date	Title
ATE141051T1 (de)	1996-08-15	Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie
HUT60138A (en)	1992-08-28	Process for producing combination compositions suitable for preventing and/or treating benign prostatic hyperplasia
ATE430568T1 (de)	2009-05-15	Verfahren und zusammensetzungen zur vorbeugung oder behandlung von atherosclerose, restenose und zusammenhängenden erkrankungen
DE69736745D1 (de)	2006-11-09	Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
ATE198706T1 (de)	2001-02-15	Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
ATE319447T1 (de)	2006-03-15	Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
AU7736300A (en)	2001-04-30	Therapeutic treatment of androgen receptor driven conditions
DE59508360D1 (de)	2000-06-21	Liposomal verkapseltes taxol, seine herstellung und seine verwendung
NO20012774D0 (no)	2001-06-06	Preparat og metode hvor det gjöres bruk av eteriske planteoljer
ATE205086T1 (de)	2001-09-15	Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
ATE192921T1 (de)	2000-06-15	Therapeutischer wirkstoff zur behandlung von melanomen
IL101574A0 (en)	1992-12-30	Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia
ATE218860T1 (de)	2002-06-15	Verwendung von 3,4-diphenylchromanen zur herstellung eines arzneimittels zur behandlung bzw. vorbeugung des prostatakarzinoms
IT1270993B (it)	1997-05-26	Derivati chinzolilamminici attivi come alfa-antagonisti
DE60313603D1 (de)	2007-06-14	Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
ATE180669T1 (de)	1999-06-15	Verwendung von pregnanderivaten zur behandlung von tumoren
RU94040886A (ru)	1996-09-20	Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
DE58904722D1 (de)	1993-07-22	Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
DE69924483D1 (de)	2005-05-04	Kombinationstherapie zur behandlung von tumoren
RU94041028A (ru)	1996-09-20	Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
DE69026511D1 (de)	1996-05-15	Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
BR9203266A (pt)	1993-04-06	Composto,formulacao farmaceutica,processo para inibir 5alfa-reductase,processos para tratar hiperplasia benigna da prostata,seborreia e alopecia androgenica
ATE106732T1 (de)	1994-06-15	Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
DE69424415D1 (de)	2000-06-15	Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE91080T1 (de)	1993-07-15	Praeparat zum vorbeugen gegen knochenschwund und zur behandlung von knochenschwund.

Legal Events

Date	Code	Title	Description
1997-02-15	UEP	Publication of translation of european patent specification
2005-12-15	REN	Ceased due to non-payment of the annual fee